Titlebook: Ovarian Cancers; Advances through Int Eric Pujade-Lauraine,Isabelle Ray-Coquard,Fabrice Book 2017 Springer International Publishing Switze

HABIT

書目名稱Ovarian Cancers影響因子(影響力)




書目名稱Ovarian Cancers影響因子(影響力)學(xué)科排名




書目名稱Ovarian Cancers網(wǎng)絡(luò)公開度




書目名稱Ovarian Cancers網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Ovarian Cancers被引頻次




書目名稱Ovarian Cancers被引頻次學(xué)科排名




書目名稱Ovarian Cancers年度引用




書目名稱Ovarian Cancers年度引用學(xué)科排名




書目名稱Ovarian Cancers讀者反饋




書目名稱Ovarian Cancers讀者反饋學(xué)科排名

moratorium

http://image.papertrans.cn/o/image/705205.jpg

Pelvic-Floor

https://doi.org/10.1007/978-3-319-32110-3Cancer therapeutics; Clinical research; Onco-fertility; Ovarian rare cancers; Quality of Life; surgical o

序曲

Clear Cell CarcinomaClear cell carcinoma (CCC) is a unique entity of adenocarcinoma of the ovary. In this chapter, we discuss the clinicopathological and molecular biological characteristics of CCC. The results of clinical trials conducted in the past strongly imply the chemoresistance of CCC, and clinical trials using targeted agents are ongoing.

amplitude

Myofibrils

Carcinoma

微生物

Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicineatment of advanced ovarian cancer..HIPEC is an innovative treatment. Before using it outside clinical trials in the case of initial treatment of advanced ovarian cancer, or in the case of the first relapse, results of large multi-institutionnal randomised trials built to assess impact on survival, are required.

殘忍

FLAIL

How to Evaluate Tumor Burden Before Therapeutic Decision serum markers, and disease extension. Here we describe more advanced techniques to assess pre-operative tumor burden, ongoing clinical trials and integrated clinical models to individualize therapeutic decision.